Abstract Biomarkers in Alzheimer's disease (AD) have the potential to allow early and more accurate diagnosis, predict disease progression, stratify individuals and track response to candidate therapies in drug trials. The first fluid biomarkers reflecting aspects of AD neuropathology were identified in cerebrospinal fluid (CSF) in the 1990s. Three CSF biomarkers (amyloid-b 1-42, total tau and phosphotau) have consistently been shown to have diagnostic utility and are incorporated into the new diagnostic criteria for AD. These markers have also been shown in longitudinal studies to predict conversion of mild cognitive impairment to AD. However, a key issue with the use of CSF biomarkers as a screening test is the invasiveness of lumbar puncture. Over the last 20 years there has been an active quest for blood biomarkers, which could be easily acquired and tested repeatedly throughout the disease course. One approach to identifying such markers is to attempt to measure candidates that have already been identified in CSF. Until recently, this approach has been limited by assay sensitivity, but newer platforms now allow single molecule-level detection. Another approach is identification of candidates in large multiplex panels that allow for multiple analytes to be quantified in parallel. While both approaches show promise, to date no blood-based biomarker or combination of biomarkers has sufficient predictive value to have utility in clinical practice. In this review, an overview of promising blood protein candidates is provided, and the challenges of validating and converting these into practicable tests are discussed.
Introduction
The neuropathological signature of Alzheimer's disease (AD) is neuronal loss with deposition of amyloid-b (Ab) in extracellular plaques and accumulation of hyper-phosphorylated tau protein in intracellular neurofibrillary tangles. Extrapolation from post-mortem studies suggests that in most cases these proteins propagate through the brain in a reliable progression, which is reflected in neuropathological staging systems for AD [1] . These studies showed that early stage AD neuropathology exists in individuals who are asymptomatic, paving the way for pre-symptomatic diagnosis and clinical trials aiming to prevent cognitive decline. Given the obvious limitations of obtaining brain tissue during life, there has been considerable interest in discovering disease-specific biomarkers both in the symptomatic and pre-symptomatic phases.
Ideal biomarkers have different characteristics based on the information they aim to give [1] . For example, an ideal diagnostic biomarker would reliably reflect in vivo pathology with high sensitivity and specificity. A screening biomarker would combine at least moderate sensitivity with high specificity and low cost. Conversely, a marker of progression may be downstream of the initial pathology but reliably track change over time. For all biomarkers, reliability, cost, and ease of acquisition and processing are important considerations.
The currently available biomarkers for AD include structural imaging (e.g. magnetic resonance imaging [MRI] and computed tomography), functional imaging (e.g. 
Cerebrospinal Fluid Biomarkers: Established and Emerging
Studies have shown that low CSF Ab42 [2] , high CSF total tau (t-tau) [3] and high CSF phospho-tau [4] in life are correlated with a clinical diagnosis of AD, and also with severity of AD pathology post-mortem [5, 6] . Moreover, several large multicentre studies have shown this pattern to predict which patients with mild cognitive impairment (MCI) will progress to AD [7] [8] [9] . This implies that the change in CSF biomarkers must occur during the preclinical stage of AD. This CSF biomarker signature is now established in both the International Working Group (IWG)-2 and National Institute on Aging (NIA) diagnostic criteria for AD, in pre-symptomatic, prodromal (MCI), typical and atypical forms of AD [3, [10] [11] [12] [13] . Newer CSF biomarkers that reflect other aspects of AD remain an active topic of research. The postsynaptic marker neurogranin has been identified in multiple cohorts as being able to differentiate AD from control with an effect size (defined as fold change in the mean biomarker concentration between AD and control groups) of 1.9 in a recent meta-analysis [14] , and to differentiate MCI patients who will progress to AD [effect size 1.5] [15] . Other studies have provided evidence that numerous other CSF markers may be able to distinguish AD from controls, including heart fatty acid binding protein [16] , neuronspecific enolase [17] , neurofilament light chain (NFL) [18] , YKL-40 [19] and visinin-like protein-1 [20] , with effect sizes ranging from 1.3 to 2.3. However, none is currently more diagnostically useful than the established markers Ab42 and tau, suggesting that the true utility of these additional markers will come from understanding their relationship to the underlying pathology, and in using them to ask more refined questions. For example, a diagnostic marker is most useful when it can differentiate AD from other dementias. This has been recently observed by Wellington et al. [21] for neurogranin, which rises specifically in AD but not in other diseases such as Lewy body dementia (LBD) and behavioural variant frontotemporal dementia (FTD) which often are in the differential diagnosis of AD. Another more specific function of a diagnostic biomarker would be to differentiate subtypes of AD. Paterson et al. [22] have shown that the latter may be the case for CSF NFL, which is higher in the CSF of patients in the frontal variant subgroup of AD than in other 'atypical' variants of AD as defined by the IWG-2 criteria; this represents a group that tends to have younger onset and more aggressive disease.
'Traditional' assay development has been on a single candidate molecule approach, devising specific enzymelinked immunosorbent assays (ELISAs) for proteins thought to be relevant to the disease. This approach has its limitations: it is slow and relies on a priori assumptions of the role of the candidate analyte in disease pathogenesis. Thus, many groups have turned to employing multiplexing approaches in CSF [23, 24] . A recent example is Heywood et al.'s mass spectrometry-based targeted proteomics assay in CSF from two independent cohorts [25] , which demonstrated 23 proteins (six of which were novel) that differentiate AD and LBD from controls. Four proteins (two of which were novel) differentiated AD from both LBD and controls. Many of these markers did not show a relationship with CSF Ab42, t-tau or phospho-tau, implying that their association with the pathology of AD may be unrelated to amyloid plaques and tau neurofibrillary tangles.
Minimally Invasive Tests
While CSF biomarkers have proven utility, obtaining CSF remains a relatively invasive procedure. Lumbar puncture is not without complications (the commonest of which is headache) and it is relatively contraindicated in patients with clotting disorders and those who are taking anticoagulant medication. It requires a skilled operator and appropriate facilities to take, process and store samples, which are sensitive to handling errors. This set of systems and processes adds to the overall cost of the test. The optimal biomarker(s) would therefore be obtained via a non-invasive, relatively cheap and easily repeatable test. Blood, which is collected paired with CSF in most major fluid biomarker research initiatives, provides this opportunity.
Blood Biomarkers

The Candidate Approach
Identification of peripheral biomarkers reflecting central nervous system (CNS) dysfunction is challenging for many reasons. First, molecules from the brain must cross the blood-brain barrier. Second, their concentration in blood is likely to be much smaller than that in CSF, due to the much higher volume of dilution in blood. Third, the high concentration of plasma proteins can be either a sink for secreted proteins from the brain (due to binding or enzymatic breakdown) or a source of similar or identical proteins. Taking the example of plasma Ab42, many of these factors come into play. Ab42 is present at very low concentrations in plasma, it is prone to plasma protein binding and may be eliminated by enzyme activity. These factors may explain why plasma Ab42 does not correlate well with the CSF profile [26] [27] [28] [29] and there are mixed reports of inverse correlation [30] and of lack of correlation [31] of plasma Ab42 with amyloid PET. Further problems with plasma Ab42 are its susceptibility to technical factors such as aliquot volume and delay to freezing samples [32] .
To date, only one blood biomarker has been shown to distinguish AD from control subjects across multiple patient populations. Plasma t-tau was shown in a recent meta-analysis across six comparisons [33, 34] to have an effect size of 1.95 (95 % CI 1.12-3.38; n = 271 AD, 394 controls). Yet even within this meta-analysis there was significant variation depending on the method used to quantify t-tau. One of these studies showed a significant inverse effect [35] and one showed no appreciable effect [36] -both used conventional ELISA methods that were not optimised to measure the low concentrations of tau in the blood. A more sensitive immunomagnetic reduction method was used in three other comparisons derived from two studies by the same group [37, 38] and showed effect sizes consistent with the results of the overall meta-analysis, but these results, using this particular measurement technique, are in need of independent replication. The final study [39] utilised a single molecular digital array platform that is able to quantify t-tau at the single molecule level and proved to have the highest sensitivity of the three methods [40] . This study compared AD with MCI and control subjects from a Swedish cohort, showing that while plasma t-tau differentiates AD from control, there is no significant effect for MCI versus control. The former finding has been replicated in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort and the Swedish BioFINDER study [41] and the latter finding has been independently replicated in a larger cohort from the Mayo Clinic Study of Aging [42] , using the same platform. While the difference in plasma t-tau levels between MCI and control did not reach statistical significance, there was a significant inverse correlation between plasma tau and cognitive performance (in the global, memory and attention/executive function domains), as well as between plasma t-tau and cortical thickness in an AD region of interest defined on MRI. A summary of the studies published thus far is provided in Table 1 .
While plasma tau shows some promise, interpretation of the various studies is not easy, given that plasma t-tau is known to vary widely even in healthy individuals; and tau elevation is not specific to AD, as it is seen in many diseases with rapid neuronal destruction (e.g. prion disease) as well as after traumatic brain injury [43] . There is also a lack of correlation between CSF and plasma t-tau within individuals [36] . Further studies in different cohorts are needed to understand what plasma tau elevation means before it can be more routinely used in research and certainly before any potential clinical translation.
Another recent advance in the blood biomarker domain is the discovery of the relationship between serum NFL and the progression of neurodegenerative diseases. NFL in CSF may discriminate FTD from other types of dementia [44] and be an indicator of disease severity in FTD [45] . More recently, there have been reports of serum NFL also reflecting disease severity in FTD [46, 47] and correlating with the annualised frontal lobe atrophy rate in FTD [47] . In an extensive body of work spanning mouse APP-PS1 (amyloid precursor protein-presenilin 1) mutant models and human CSF and blood sampling, Bacioglu et al. [48] showed that both CSF and serum NFL are raised in AD compared with control patients. Serum NFL was highest in patients with tauopathies (with effect sizes *3 to 6) and moderately high in those with AD and atypical parkinsonian syndromes (with effect sizes *3), but was no different in those with idiopathic Parkinson's disease compared with controls, lending support to the view that this may be a useful test in distinguishing idiopathic Parkinson's disease from atypical parkinsonism. Serum NFL broadly correlated with CSF within individuals (a finding that has been corroborated by others for both serum [49] and plasma [50] ) and also correlated with Mini-Mental State Examination scores. Treatment of the mouse APP-PS1 models with a b-secretase-1 inhibitor, which reduces the generation of Ab42 and the formation of amyloid plaques, led to a reduction in both CSF and plasma NFL, which was not observed in the untreated APP-PS1 mice. Taken together, these findings raise the prospect of using blood NFL as a possible treatment response biomarker in AD trials, as, unlike plasma t-tau, serum NFL seems to track the CSF levels and the progression of disease. Notably, a statistically significant elevation in serum NFL was not seen in MCI, but this may yet change as serum NFL is measured in pre-symptomatic and mildly symptomatic subjects (such as in the Dominantly Inherited Alzheimer's Network cohort) with higher sensitivity assays such as single molecular array. It will be interesting in such cohorts to determine whether models that combine serum NFL levels with serial MRI data could provide more predictive value for disease severity than using either test alone.
Any such efforts will need to adopt a standardised approach across centres to allow for cross-validation, and there is now an international working group pre-analytic processing guideline [51] , which will continue to evolve as additional research findings become available. The guideline refers to ''controllable'' and ''uncontrollable'' variables. These match technical variables (in blood collection/ handling/storage) and patient factors (such as demographics, genotype, co-morbidities and lifestyle factors), respectively. While the former should be standardised, collecting information on the latter will allow for stratification and interesting between-group comparisons that may ultimately inform the application of a particular biomarker as a screening, diagnostic, prognostic or therapeutic indicator.
Multiplexing
As has occurred in the CSF field, multiplexing approaches to plasma proteomics have been employed by several investigators in an effort to define groups of proteins that may inform pathways to the development and progression Control (35) MCI (33) AD (34) IPD (32) DLB (20) MSA (17) PSP (24) CBS ( of AD. A selection of some notable studies is provided in Table 2 . The earliest of these studies, by Ray et al. [52] in 2007, used a sandwich ELISA immunoassay platform and identified an 18-analyte panel of proteins that segregated AD from controls. However, in an attempt at replication in another cohort (ADNI), by using seven of the analytes that gave a combined diagnostic accuracy of 90 % in the Ray et al. [52] study, 61 % diagnostic accuracy was achieved, and the incorporation of a different 89-analyte panel increased this to 70 % [53] . These results, however, have been difficult to replicate [54, 55] . Doecke et al. [56] crossvalidated panels of biomarkers obtained from AIBL (Australian Imaging, Biomarkers and Lifestyle study) against ADNI, and found just two biomarkers that had individual effect sizes greater than 1.5 that were common to both cohorts: insulin-like growth factor binding protein 2 and pancreatic polypeptide. However, when a multivariate model using a panel of eight plasma biomarkers was added to the predictive capacity of a model based on age, sex and APOE genotype, the biomarker panel was only able to increase sensitivity and specificity from 77 to 83 %. This emphasises the importance of assessing how much actual additional predictive information is provided by these tests, as it ultimately relates to the cost-benefit analyses that will determine their ability to translate into more general research or clinical settings. Other multiplexing techniques have used mass spectroscopy, preceded by either liquid chromatography or differential matrix or surface adsorption to enrich samples for proteins at low concentration. While this type of approach does not rely on the availability of specific antibodies to the analytes of interest, it is this very point that makes the data noisy. Zhang et al. [57] piloted this approach by identifying four proteins in AD versus control sera, using mass spectroscopy, which was then cross-validated using immunoassays (ELISA and Western blot). Similar methods have been employed to compare signatures of metabolites in CSF and plasma of controls, MCI and AD patients [58] . A newer method is the use of aptamer-based microarrays, which use oligonucleotides that function with high specificity, almost like 'chemical antibodies', but are more thermally stable and might therefore be more clinically translatable [59] .
Multiplexing provides clear advantages by allowing large numbers of candidate biomarkers to be screened, provided that these replicate well across cross-sectional and longitudinal cohorts. Although to date replication has largely been lacking, the primary 'hits' obtained so far have often segregated into classes of proteins identified from other realms of biology, for example from the 'inflammatory cascade', 'lipid metabolism', 'complement' and other groups. However, it is uncertain to what extent one can extrapolate the role of these proteins from blood to a distant underlying pathology in the CNS. Data-driven approaches also have other disadvantages. Firstly, to quote Lopez et al. [60] , ''Given a sufficiently large pool of potential proteins and peptides, one is almost certain to identify a pattern that discriminates between persons with and without disease within any given data set''. This is the age-old problem of multivariate analysis, which can be mitigated to some extent by statistical rigour, but ultimately requires replication in independent cohorts. Secondly, biomarkers may be able to answer more powerful questions if their relationship to pathology, and indeed to factors such as healthy aging or other dementia pathologies, is known. We can begin to derive such knowledge by integrating diverse research tools such as genomics and transcriptomics with proteomics. A recent example is the work of Jaeger et al. [61] who used an in-house immune microarray to probe a library of 600 secreted signaling proteins in plasma from AD patients, semantic dementia patients and healthy controls. They identified protein clusters that map to 'complement', 'apoptosis' and 'regulation of growth', many of which were hits on previous multiplex analyses, but a novel pathway, the TGFb/GDF/ BMP (transforming growth factor-b/growth differentiation factor/bone morphogenetic protein) cluster, was identified. The potential relevance of this pathway was supported through the demonstration of a large number of single nucleotide polymorphisms at the gene level in AD patients, and correlation with lower GDF3 protein levels in postmortem cortical extracts from AD patients. Whilst replication in other cohorts and validation using more conventional immunoassays such as ELISA will be required, the identification of this pathway illustrates that an integrated approach may prove to be a way of discovering new biomarkers and elucidating their function, with the ultimate aim of identifying therapeutic targets.
Moving Forward
Despite the inherent problems in developing blood-based biomarkers that accurately reflect brain biochemistry, ever more sensitive instruments and unbiased methodologies to screen large numbers of proteins concurrently mean that there is now a very real prospect of clinically useful bloodbased biomarkers for AD. Blood measures of tau and of NFL are currently leading blood-based biomarker candidates; further work is required to understand what role they may play as diagnostic, prognostic or outcome measures in AD.
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